Q2 Net revenue grew 73% year-over-year to approximately
Q2 Total active members grew more than 40% year-over-year to approximately 61,500
Reaffirm FY 2021 Net revenue guidance, expecting 64% year-over-year growth
Second Quarter 2021 Financial Highlights
The following table summarizes the Company’s performance during the second quarter of 2021, compared to the same period in 2020:
| Three Months Ended |
Period-Over-Period | ||||||||
(amounts in thousands, except percentages) | 2021 | 2020 | Change | |||||||
Number of B2B eligible lives at period end | 56,039.0 | 33,560.5 | 67.0% | |||||||
Total number of active members at period end | 61.5 | 43.5 | 41.5% | |||||||
Net revenue | $ | 30,983 | $ | 17,877 | 73.3% | |||||
Gross profit | 19,286 | 12,307 | 56.7% | |||||||
Gross margin % | 62.2% | 68.8% | (660) basis points | |||||||
Operating expenses | 46,847 | 12,948 | 261.8% | |||||||
Net loss | 30,441 | 646 | * | |||||||
Adjusted EBITDA (1) | $ | (11,872 | ) | $ | (291 | ) | * |
* - not meaningful
(1) Adjusted EBITDA is a non-GAAP financial measure. Refer to “Reconciliation of Non-GAAP Results to GAAP Results” table below.
Outlook for Third Quarter 2021 and Full Fiscal Year 2021
The Company is reaffirming its net revenue guidance of
Conference Call Details
The Company will host a conference call at
Key Business Metrics
Active Members: We consider members “active” (i) in the case of our B2C members, commencing on the date such member initiates contact with a provider on our platform until the term of their monthly, quarterly or bi-annual subscription plan expires, unless terminated early, and (ii) in the case of our B2B members, if such members have engaged on our platform during the preceding 25 days, such as sending a text, video or audio message to, or participating in a video call with, a provider, completing a satisfaction or progress report survey or signing up for our platform.
B2B Eligible Lives: We consider B2B lives “eligible” if such persons are eligible to receive treatment on the
About
Today, the need for care feels more urgent than ever. When seeking treatment, whether it's psychiatry or adolescent, individual or couples therapy,
For more information about
Forward Looking Statements
This press release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking, including statements regarding our financial condition, anticipated financial performance, business strategy and plans, market opportunity and expansion and objectives of our management for future operations. These forward-looking statements generally are identified by the words “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “forecast”, “future”, “intend,” “may,” “might”, “opportunity”, “plan,” “possible”, “potential,” “predict,” “project,” “should,” “strategy”, “strive”, “target,” “will,” or “would”, the negative of these words or other similar terms or expressions. The absence of these words does not mean that a statement is not forward-looking. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many important factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: our history of losses; the rapid evolution of our business and the markets in which we operate; our ability to continue growing at the rates we have historically grown, or at all; the development of the virtual behavioral health market; COVID-19 and its impact on business and economic conditions; competition in our industry; and our relationships with affiliated professional entities to provide physician and other professional services. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in under the caption “Risk Factors” in our prospectus dated
Contacts
For Investors:
Westwicke, an
443-213-0500
TalkspaceIR@westwicke.com
For Media:
SKDK
310-997-5963
jkim@skdknick.com
Condensed Consolidated Statements of Loss
(Unaudited)
Three months ended |
Variance | Six months ended |
Variance | |||||||||||||||||||||||||||||
2021 | 2020 | $ | % | 2021 | 2020 | $ | % | |||||||||||||||||||||||||
($ in thousands) | ($ in thousands) | |||||||||||||||||||||||||||||||
Revenues | $ | 30,983 | $ | 17,877 | $ | 13,106 | 73.3 | $ | 58,140 | $ | 28,997 | $ | 29,143 | 100.5 | ||||||||||||||||||
Cost of revenues | 11,697 | 5,570 | 6,127 | 110.0 | 21,511 | 10,980 | 10,531 | 95.9 | ||||||||||||||||||||||||
Gross profit | 19,286 | 12,307 | 6,979 | 56.7 | 36,629 | 18,017 | 18,612 | 103.3 | ||||||||||||||||||||||||
Operating expenses: | ||||||||||||||||||||||||||||||||
Research and development, net | 4,781 | 2,400 | 2,381 | 99.2 | 7,745 | 5,128 | 2,617 | 51.0 | ||||||||||||||||||||||||
Clinical operations | 1,913 | 759 | 1,154 | 152.0 | 3,990 | 1,636 | 2,354 | 143.9 | ||||||||||||||||||||||||
Sales and marketing | 26,443 | 8,442 | 18,001 | 213.2 | 48,694 | 17,360 | 31,334 | 180.5 | ||||||||||||||||||||||||
General and administrative | 13,710 | 1,347 | 12,363 | 917.8 | 16,318 | 2,461 | 13,857 | 563.1 | ||||||||||||||||||||||||
Total operating expenses | 46,847 | 12,948 | 33,899 | 261.8 | 76,747 | 26,585 | 50,162 | 188.7 | ||||||||||||||||||||||||
Operating loss | 27,561 | 641 | 26,920 | * | 40,118 | 8,568 | 31,550 | 368.2 | ||||||||||||||||||||||||
Financial expenses (income), net | 2,870 | (1 | ) | 2,871 | * | 3,043 | (31 | ) | 3,074 | * | ||||||||||||||||||||||
Loss before taxes on income | 30,431 | 640 | 29,791 | * | 43,161 | 8,537 | 34,624 | 405.6 | ||||||||||||||||||||||||
Taxes on income | 10 | 6 | 4 | 66.7 | 18 | 9 | 9 | 100.0 | ||||||||||||||||||||||||
Net loss | $ | 30,441 | $ | 646 | $ | 29,795 | * | $ | 43,179 | $ | 8,546 | $ | 34,633 | 405.3 |
* = not meaningful
Condensed Consolidated Balance Sheets
(Unaudited) | ||||||||
ASSETS | | |||||||
CURRENT ASSETS: | | | ||||||
Cash and cash equivalents | $ | 248,173 | $ | 13,248 | ||||
Accounts receivable | 6,617 | 5,914 | ||||||
Other current assets | 4,318 | 1,515 | ||||||
Total current assets | 259,108 | 20,677 | ||||||
Property and equipment, net | 549 | 175 | ||||||
Deferred issuance costs | - | 692 | ||||||
Intangible assets, net | 4,315 | 5,195 | ||||||
6,134 | 6,134 | |||||||
Other long-term assets | 98 | - | ||||||
Total assets | $ | 270,204 | $ | 32,873 | ||||
LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ DEFICIT |
| | ||||||
CURRENT LIABILITIES: | | | ||||||
Accounts payable | $ | 11,759 | $ | 7,901 | ||||
Deferred revenues | 7,549 | 5,172 | ||||||
Accrued expenses and other current liabilities | 9,640 | 7,416 | ||||||
Total current liabilities | 28,948 | 20,489 | ||||||
Warrant liabilities | 38,897 | - | ||||||
Other long-term liabilities | 98 | - | ||||||
Total liabilities | 67,943 | 20,489 | ||||||
Convertible preferred stock | - | 111,282 | ||||||
STOCKHOLDERS’ DEFICIT: | | | ||||||
Common stock | 15 | 1 | ||||||
Additional paid-in capital | 354,213 | 9,889 | ||||||
Accumulated deficit | (151,967 | ) | (108,788 | ) | ||||
Total stockholders’ deficit | 202,261 | (98,898 | ) | |||||
Total liabilities, convertible preferred stock and stockholders’ deficit | $ | 270,204 | $ | 32,873 | ||||
Condensed Consolidated Statements of Cash Flows
(Unaudited)
Six months ended |
||||||||
2021 | 2020 | |||||||
Cash flows from operating activities: | ||||||||
Net loss | $ | (43,179 | ) | $ | (8,546 | ) | ||
Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
Depreciation and amortization | 955 | 36 | ||||||
Amortization of debt issuance cost | 175 | — | ||||||
Stock-based compensation | 16,709 | 733 | ||||||
Change in fair value of warrants | 3,043 | — | ||||||
Increase in accounts receivable | (703 | ) | (785 | ) | ||||
Increase in other current assets | (1,784 | ) | (556 | ) | ||||
Increase (decrease) in accounts payable | 4,833 | (326 | ) | |||||
Increase in deferred revenues | 2,377 | 2,068 | ||||||
Decrease in accrued expenses and other current liabilities | (213 | ) | (286 | ) | ||||
Net cash used in operating activities | (17,787 | ) | (7,662 | ) | ||||
Cash flows from investing activities: | ||||||||
Purchase of property and equipment | (449 | ) | (9 | ) | ||||
Net cash used in investing activities | (449 | ) | (9 | ) | ||||
Cash flows from financing activities: | ||||||||
Proceeds from reverse capitalization, net of transaction costs | 251,325 | — | ||||||
Proceeds from borrowings | 6,000 | — | ||||||
Repayment of borrowings | (6,000 | ) | — | |||||
Payment of debt issuance costs | (50 | ) | — | |||||
Proceeds from exercise of stock options | 1,886 | 62 | ||||||
Net cash provided by financing activities | 253,161 | 62 | ||||||
Change in cash and cash equivalents | 234,925 | (7,609 | ) | |||||
Cash and cash equivalents at the beginning of the period | 13,248 | 39,632 | ||||||
Cash and cash equivalents at the end of the period | $ | 248,173 | $ | 32,023 |
Non-GAAP Financial Measures
In addition to our financial results determined in accordance with GAAP, we believe adjusted EBITDA, a non-GAAP measure, is useful in evaluating our operating performance. We use adjusted EBITDA to evaluate our ongoing operations and for internal planning and forecasting purposes. We believe that this non-GAAP financial measure, when taken together with the corresponding GAAP financial measures, provides meaningful supplemental information regarding our performance by excluding certain items that may not be indicative of our business, results of operations or outlook. We believe that the use of adjusted EBITDA is helpful to our investors as it is a metric used by management in assessing the health of our business and our operating performance. However, non-GAAP financial information is presented for supplemental informational purposes only, has limitations as an analytical tool and should not be considered in isolation or as a substitute for financial information presented in accordance with GAAP. In addition, other companies, including companies in our industry, may calculate similarly titled non-GAAP measures differently or may use other measures to evaluate their performance, all of which could reduce the usefulness of our non-GAAP financial measure as a tool for comparison. A reconciliation is provided below for this non-GAAP financial measure to net loss, the most directly comparable financial measure stated in accordance with GAAP. Investors are encouraged to review our GAAP financial measure and the reconciliation of our non-GAAP financial measure to its most directly comparable GAAP financial measure, and not to rely on any single financial measure to evaluate our business.
Adjusted EBITDA
Adjusted EBITDA is a key performance measure that our management uses to assess our operating performance. Because adjusted EBITDA facilitates internal comparisons of our historical operating performance on a more consistent basis, we use this measure for business planning purposes and in evaluating acquisition opportunities.
We calculate adjusted EBITDA as net loss adjusted to exclude (i) interest and other expenses (income), net, (ii) tax benefit and expense, (iii) depreciation and amortization (iv) stock-based compensation expense and (v) business combination and other financing expenses.
Reconciliation of Non-GAAP Results to GAAP Results
Three months ended |
Six months ended |
|||||||||||||||
(in thousands) | 2021 | 2020 | 2021 | 2020 | ||||||||||||
Net loss | $ | (30,441 | ) | $ | (646 | ) | $ | (43,179 | ) | $ | (8,546 | ) | ||||
Add: | ||||||||||||||||
Depreciation and amortization | 493 | 18 | 955 | 36 | ||||||||||||
Financial expense (income), net (1) | 2,870 | (1 | ) | 3,043 | (31 | ) | ||||||||||
Taxes on income | 10 | 6 | 18 | 9 | ||||||||||||
Stock-based compensation | 15,196 | 332 | 16,709 | 733 | ||||||||||||
Adjusted EBITDA | $ | (11,872 | ) | $ | (291 | ) | $ | (22,454 | ) | $ | (7,799 | ) | ||||
(1) For the three months ended
Source: Talkspace